| Description | Iniparib (BSI-201) (BSI-201) , a PARP1 inhibitor, exhibits potency in triple-negative breast Y (TNBC). |
| In vivo | 在855-2 细胞中, BSI-201（120 μM） 和buthionine sulfoximine联用可诱导细胞死亡达95%,作用于其他人类肿瘤细胞效果差不多。在E-ras 20 细胞中,BSI-201可抑制细胞生长,与buthionine sulfoximine联用,效果则增强20倍。人淋巴细胞系中,BSI-201（100 μM）可抑制电离辐射诱导的单链断裂 (SSBs) 修复。 |
| Cell experiments | Cells are exposed to various concentrations of BSI-201 for 5, and 9 days in the presence or absence of buthionine sulfoxamide (BSO). After treatment, cell proliferation is measured by CellTiter-Glo assay.(Only for Reference) |
| Synonyms | NSC-746045, IND-71677, 3-硝基-4-碘苯甲酰胺, BSI-201 |
| molecular weight | 292.03 |
| Molecular formula | C7H5IN2O3 |
| CAS | 160003-66-7 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | Ethanol: 14.6 mg/mL (50 mM) DMSO: 85 mg/mL (291.07 mM), Sonication is recommended. |
| References | 1. Mendeleyev J, et al. Biochem Pharmacol, 1995, 50(5), 705-714. 2. Bauer PI, et al. Biochem Pharmacol, 2002, 63(3), 455-462. 3. Liu X, et al. Clin Cancer Res, 2012, 18(2), 510-523. 4. Ma W, et al. Proc Natl Acad Sci U S A, 2012, 109(17), 6590-6595. 5. Patel AG, et al. Clin Cancer Res, 2012, 18(6), 1655-1662. 6. Yin S, et al. Myc mediates cancer stem-like cells and EMT changes in triple negative breast cancers cells. PLoS One. 2017 Aug 17;12(8):e0183578. |